DFDi Fan

Di Fan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Di Fan has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ADAMTS4 mediates LPS‐induced cardiac injury and myocardial fibrosis through proteolytic cleavage of TSP1

    by Zhe‐Wei Zhang, Shi‐Yan Wan, Wen Li, Xiao Lu, Rong Chen, Xin Xing, Wei Lai, Shu‐Yang Sheng, M. M. Mosebetsi, Qing‐Tao Meng, et al.

    Septic cardiomyopathy is characterized by acute cardiac dysfunction, while sustained inflammatory and extracellular matrix remodeling may contribute to subsequent myocardial fibrosis and impaired cardiac recovery. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) has been linked to fibrotic remodelling, but its role in septic cardiac injury remains unclear. Here, we show that Adamts4 is upregulated in LPS‐induced septic mouse hearts and is predominantly induced in cardiac fibroblasts. Using three fibroblast‐lineage Adamts4 knockout models, we demonstrate that Adamts4 deletion attenuates LPS‐induced cardiac dysfunction, inflammation and fibrosis, whereas Tcf21‐lineage fibroblast Adamts4 overexpression aggravates these changes. Mechanistically, ADAMTS4 interacts with thrombospondin‐1 (TSP1) and promotes its catalytic activity‐dependent proteolytic processing. The 236–246 amino acid region of TSP1 is required for fragment generation and fibroblast activation. TSP1 processing further activates TGF‐β/Smad and NF‐κB signalling, promoting myofibroblast activation and extracellular matrix deposition. These findings identify ADAMTS4 as a fibroblast‐centred driver of septic cardiac fibrosis and suggest that targeting the ADAMTS4‐TSP1 axis may offer therapeutic potential for septic cardiomyopathy. Key Points: ADAMTS4 is induced predominantly in cardiac fibroblasts after LPS challenge Fibroblast‐lineage Adamts4 deletion attenuates LPS‐induced cardiac dysfunction and fibrosis The TSP1 236‐246 aa region is required for efficient ADAMTS4‐dependent processing ADAMTS4‐dependent TSP1 processing activates TGF‐β/Smad and NF‐κB signalling in fibroblasts.

  • Top Cited Papers

    Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction

    by Ke-Qiong Deng, Zhendong Xu, Qiongxin Wang, Huan-Huan Cai, Di Fan, Qingqing Wu, Xiao-Jing Zhang, Peng Zhang, Zhi-Gang She, Xingguo Liu, et al.

    BACKGROUND: Mitophagy is critically involved in cardiac injury and repair after myocardial infarction (MI), whereas the annexin A family plays an important role in mitophagy. However, the intrinsic molecular underpinnings that orchestrate the homeostasis of mitophagy in the infarcted heart remain to be fully characterized. Here, we aimed to evaluate the role of ANXA2 (annexin A2) in cardiac mitophagy in response to MI. METHODS: Transcriptome analyses were conducted to identify differentially expressed genes and enriched pathways. Mitophagy, mitochondrial function, and cardiac injury and remodeling were analyzed in MI mice and neonatal rat ventricular myocytes with cardiomyocyte-specific Anxa2 knockdown or overexpression, as well as in models with Anxa2 knockdown combined with Phb2 (prohibitin 2) silencing. Immunoprecipitation, mass spectrometry, and glutathione S-transferase pull-down assays were used to identify the interacting proteins of ANXA2. RESULTS: We showed that ANXA2 was highly expressed in murine and human ischemic failing hearts, whereas increased circulating ANXA2 positively correlated with cardiac injury in patients with acute MI. Moreover, cardiomyocyte-specific Anxa2 depletion averted cardiac mitophagy inactivation, oxidative stress, cell death, and inflammatory cell infiltration, leading to significant improvements in infarct size, heart function, and cardiac remodeling after MI. Conversely, Anxa2 overexpression in cardiomyocytes suppressed mitophagy to exacerbate cardiac injury and deteriorate heart failure after MI. Moreover, Anxa2 silencing and overexpression, respectively, in neonatal rat ventricular myocytes under hypoxia in vitro recapitulated the in vivo findings on mitochondrial function and cell death. Mechanistically, we found that ANXA2 directly interacted with the mitophagy receptor PHB2 to competitively block the binding of LC3B (microtubule-associated protein 1 light chain 3 beta) with PHB2 and promote PHB2 proteasomal degradation through K48-linked polyubiquitination mediated by the E3 ligase TRIM29 (tripartite motif-containing 29), resulting in mitophagy inhibition under hypoxia. Consequently, Phb2 knockdown abrogated the protective effects of Anxa2 deficiency on mitochondrial function, oxidative stress, and cell viability in stressed myocytes in vitro, as well as on heart function and remodeling under MI in vivo. CONCLUSIONS: These findings highlight the significance of ANXA2 inhibition as a molecular brake on mitophagy inactivation in cardiomyocytes under MI and uncover an ANXA2-mediated posttranslational mechanism essential for maintaining mitochondrial homeostasis and alleviating heart failure after MI.


  • Open Access

    Editorial: The role of inflammation in organ injury

    by Zhen Guo, Di Fan

    Inflammation represents one of the most fundamental and evolutionarily conserved biological responses for host defense against pathogens and tissue injury (1). However, Inflammation can transition from a protective mechanism to a pathogenic one, contributing significantly to organ dysfunction and failure across diverse clinical contexts. This Research Topic was conceived to address the critical knowledge gaps in our understanding of how inflammatory processes contribute to organ dysfunction, with the dual aims of identifying novel therapeutic targets and advancing precision medicine approaches to inflammatory diseases.The concept of systemic inflammatory response syndrome and its progression to a mechanism of multi-organ dysfunction has been extensively studied, yet the precise mechanisms by which local inflammatory responses propagate to cause distant organ failure remain incompletely understood. This collection provides evidence for the interconnected nature of inflammatory responses across organ systems. Chang et al. show how co-infections in COVID-19 patients create a storm of inflammatory mediators, leading to coagulopathy and myocardial injury that significantly worsens patient outcomes. Their findings align with established concepts of cytokine storm syndrome but provide novel insights into how secondary infections can amplify the initial inflammatory insult (2). Similarly, Li et al. reveal the intricate relationship between metabolic dysfunction and inflammatory susceptibility in their study of obstructive jaundice, showing that cholestasis primes the inflammatory system for exaggerated responses to endotoxins. This work extends previous observations about the gut-liver axis and demonstrates how organ-specific dysfunction can systemically alter inflammatory responsiveness(3).The respiratory system emerges as both a primary target and a driver of systemic inflammation in several studies within this collection. The comprehensive analysis of sepsis-associated acute respiratory distress syndrome presented here builds upon decades of research into acute lung injury, providing updated perspectives on pathomechanisms and therapeutic approaches. The persistent challenges in managing SA-ARDS underscore the need for paradigm shifts in our approach to pulmonary inflammation, particularly given the heterogeneity of ARDS phenotypes and the limited success of traditional anti-inflammatory strategies(4). Suchankova et al. contribute a particularly valuable perspective by identifying CD44 as a reliable biomarker for pulmonary fibrosis progression, addressing a critical clinical need for early detection of fibrotic transformation. Their work connects cellular activation patterns with clinical outcomes, demonstrating how inflammatory cell activation leads to the uncontrolled extracellular matrix deposition characteristic of progressive fibrosis. This finding is particularly relevant given the growing recognition that many respiratory infections, including SARS-CoV-2, can result in long-term pulmonary complications (5).The study by Wawryk-Gawda et al. on e-cigarette vapor exposure provides timely insights into emerging public health concerns, revealing that alternative smoking products can trigger robust inflammatory responses that may be distinct from those induced by traditional cigarette smoking. Their observation that inflammatory effects are largely reversible upon cessation, with the notable exception of certain cytokines that persist longer in traditional cigarette users, has important implications for public health policy and cessation strategies. This work contributes to our understanding of how different inflammatory triggers can produce overlapping yet distinct pathological signatures.Cardiovascular inflammation represents another critical domain where this collection makes significant contributions. Cao et al. employ sophisticated Mendelian randomization approaches to establish causal relationships between specific immune cell populations and heart failure risk, moving beyond simple associations to demonstrate true causal relationships. Their identification of 40 immunophenotypes with significant causal relationships to heart failure provides a roadmap for future therapeutic targeting and represents a significant advance in our understanding of immune-mediated cardiac dysfunction (6). The intersection of cardiovascular and immune systems is further explored by Kristoffersson et al., who reveal unexpected interactions between the renin-angiotensin system and complement activation. Their demonstration that renin can directly cleave C3 to generate bioactive complement fragments challenges traditional views of these systems as independent and suggests novel therapeutic opportunities at their interface.The neuroinflammatory components of organ injury are addressed through multiple perspectives in this collection. Ali et al. examined hypercholesterolemia's impact on post-stroke inflammation demonstrates how metabolic comorbidities can profoundly alter the brain's inflammatory response to injury, leading to larger infarcts and worse outcomes. This work extends previous observations about the role of cholesterol in neuroinflammation and provides mechanistic insights into why patients with metabolic syndrome often experience worse stroke outcomes (7). Wu et al. provide a comprehensive analysis of diabetic neuropathic pain that delivers crucial insights into how chronic inflammatory states can lead to persistent neurological dysfunction, emphasizing the complex interplay between metabolic dysfunction, inflammatory mediators, and ion channel regulation in pain pathogenesis.Renal inflammation represents a particularly well-characterized example of how inflammatory processes can lead to progressive organ dysfunction. Zhu et al. present groundbreaking work on HMGB1 lactylation and its role in driving the formation neutrophil extracellular traps in acute kidney injury, providing a mechanistic...


  • Open Access

    MEGF9 prevents lipopolysaccharide-induced cardiac dysfunction through activating AMPK pathway

    by Zhili Jin, Xianqing Li, Huixia Liu, Tao He, Wanli Jiang, Li Peng, Xiaoyan Wu, Ming Chen, Yongzhen Fan, Zhibing Lu, et al.

    Inflammation and oxidative damage play critical roles in the pathogenesis of sepsis-induced cardiac dysfunction. Multiple EGF-like domains 9 (MEGF9) is essential for cell homeostasis; however, its role and mechanism in sepsis-induced cardiac injury and impairment remain unclear. Adenoviral and adeno-associated viral vectors were applied to overexpress or knock down the expression of MEGF9 in vivo and in vitro. To stimulate septic injury, cardiomyocytes and mice were treated lipopolysaccharide (LPS). To clarify the necessity of AMP-activated protein kinase (AMPK), global AMPK knockout mice were used. We found that MEGF9 expressions were reduced in cardiomyocytes and mice by LPS stimulation. Compared with negative controls, plasma MEGF9 levels were also decreased in septic patients, and negatively correlated with LPS-induced cardiac dysfunction. In addition, MEGF9 overexpression attenuated, while MEGF9 knockdown aggravated LPS-induced inflammation and oxidative damage in vivo and in vitro, thereby regulating LPS-induced cardiac injury and impairment. Mechanistic studies revealed that MEGF9 overexpression alleviated LPS-induced cardiac dysfunction through activating AMPK pathway. We for the first time demonstrate that MEGF9 prevents LPS-related inflammation, oxidative damage and cardiac injury through activating AMPK pathway, and provide a proof-of-concept for the treatment of LPS-induced cardiac dysfunction by targeting MEGF9.


  • Dexamethasone eluting polydopaminated polycaprolactone‐poly (lactic‐co‐glycolic) acid for treatment of tracheal stenosis

    by Jacob Morand, Phillip McClellan, Ilaha Isali, Yusuf Dikici, Di Fan, Longshun Li, Andrew J. Shoffstall, Ozan Akkus, Mark Weidenbecher

    Tracheal stenosis is commonly caused by injury, resulting in inflammation and fibrosis. Inhibiting inflammation and promoting epithelization can reduce recurrence after initial successful treatment of tracheal stenosis. Steroids play an important role in tracheal stenosis management. This study in vitro evaluated effectiveness of a polydopaminated polycaprolactone stent coated with dexamethasone‐eluting poly(lactic‐co‐glycolic) acid microparticles (μPLGA) for tracheal stenosis management. Polydopamination was characterized by Raman spectroscopy and promoted epithelialization while dexamethasone delivery reduced macrophage activity, assessed by individual cell area measurements and immunofluorescent staining for inducible nitric oxide synthase (iNOS). Dexamethasone release was quantified by high‐performance liquid chromatography over 30 days. Activation‐related increase in cell area and iNOS production by RAW 264.7 were both reduced significantly (p < .05) through dexamethasone release. Epithelial cell spreading was higher on polydopaminated polycaprolactone (PCL) than PCL‐alone (p < .05). Force required for stent migration was measured by pullout tests of PCL‐μPLGA stents from cadaveric rabbit and porcine tracheas (0.425 ± 0.068 N and 1.082 ± 0.064 N, respectively) were above forces estimated to occur during forced respiration. Biomechanical support provided by stents to prevent airway collapse was assessed by comparing compressive circumferential stiffness, and stiffness of the stent was about 1/10th of the rabbit trachea (0.156 ± 0.023 N/mm vs. 1.420 ± 0.194 N/mm, respectively). A dexamethasone‐loaded PCL‐μPLGA stent platform can deliver dexamethasone and exhibits sufficient mechanical properties to anchor within the trachea and polydopamination of PCL is conducive to epithelial layer formation. Therefore, a polydopaminated PCL‐μPLGA stent is a promising candidate for in vivo evaluation for treatment of tracheal restenosis.


  • MiR-24-3p Attenuates Doxorubicin-induced Cardiotoxicity via the Nrf2 Pathway in Mice

    by Di Fan, Hong-Bin Chen, Yan Leng, Shi-Jun Yang

    Objective The nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) is associated with doxorubicin (DOX)-induced cardiac injury. It has been reported that microRNA-24-3p (miR-24-3p) may regulate the Keapl by mRNA degradation, whereas Keapl can suppress the activation of Nrf2. However, the role of miR-24-3p in DOX-related cardiotoxicity remains unclear. Methods The mice receiving DOX were used as cardiac injury model. In this study, an adenoassociated virus 9 system was used to deliver miR-24-3p or miR-scramble to mice hearts. The echocardiographic and hemodynamic analyses were used to evaluate the effects of miR-24-3p on cardiac function under DOX stimulation. ELISA and RT-PCR were used to detect protein or mRNA expressions associated with cardiac injury, inflammation response, apoptosis and oxidative stress. Western Blot were used for quantitative analysis of the roles of miR-24-3p in regulating Nrf2 expression. H9C2 cells used to verify the role of miR-24-3p in vitro. Results We found that miR-24-3p mRNA was significantly decreased in DOX-treated mice and cardiomyocytes. Overexpression of miR-24-3p blocked cardiac injury caused by DOX injection, as reflected by the reduction in the levels of cardiac troponin I, creatinine kinase isoenzyme MB and the N-terminal pro brain natriuretic peptide. Furthermore, miR-24-3p reduced oxidative stress and cell loss without affecting the inflammation response. As expected, we found that Nrf2 was upregulated by miR-24-3p supplementation, and that the protective efforts of miR-24-3p supplementation were abolished when Nrf2 was silenced. Conclusion The results from this study suggest that miR-24-3p protects cardiomyocytes against DOX-induced heart injury via activation of the Nrf2 pathway. miR-24-3p supplementation may be a novel strategy to counteract the cardiac side effects of DOX treatment.


  • Open Access

    Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy

    by Dan Yang, Han-Qing Liu, Fang-Yuan Liu, Zhen Guo, Peng An, Ming-Yu Wang, Zheng Yang, Di Fan, Qi-Zhu Tang

    Cardiac hypertrophy, a stereotypic cardiac response to increased workload, ultimately progresses to severe contractile dysfunction and uncompensated heart failure without appropriate intervention. Sustained cardiac overload inevitably results in high energy consumption, thus breaking the balance between mitochondrial energy supply and cardiac energy demand. In recent years, accumulating evidence has indicated that mitochondrial dysfunction is implicated in pathological cardiac hypertrophy. The significant alterations in mitochondrial energetics and mitochondrial proteome composition, as well as the altered expression of transcripts that have an impact on mitochondrial structure and function, may contribute to the initiation and progression of cardiac hypertrophy. This article presents a summary review of the morphological and functional changes of mitochondria during the hypertrophic response, followed by an overview of the latest research progress on the significant modulatory roles of mitochondria in cardiac hypertrophy. Our article is also to summarize the strategies of mitochondria-targeting as therapeutic targets to treat cardiac hypertrophy.


  • Open Access

    Neuraminidase 1 deficiency attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice

    by Zhen Guo, Hu Tuo, Nan Tang, Fang-Yuan Liu, Shu-Qing Ma, Peng An, Dan Yang, Min-Yu Wang, Di Fan, Zheng Yang, et al.

    Diabetic cardiomyopathy (DCM) is associated with oxidative stress and augmented inflammation in the heart. Neuraminidases (NEU) 1 has initially been described as a lysosomal protein which plays a role in the catabolism of glycosylated proteins. We investigated the role of NEU1 in the myocardium in diabetic heart. Streptozotocin (STZ) was injected intraperitoneally to induce diabetes in mice. Neonatal rat ventricular myocytes (NRVMs) were used to verify the effect of shNEU1 in vitro. NEU1 is up-regulated in cardiomyocytes under diabetic conditions. NEU1 inhibition alleviated oxidative stress, inflammation and apoptosis, and improved cardiac function in STZ-induced diabetic mice. Furthermore, NEU1 inhibition also attenuated the high glucose-induced increased reactive oxygen species generation, inflammation and, cell death in vitro. ShNEU1 activated Sirtuin 3 (SIRT3) signaling pathway, and SIRT3 deficiency blocked shNEU1-mediated cardioprotective effects in vitro. More importantly, we found AMPKα was responsible for the elevation of SIRT3 expression via AMPKα-deficiency studies in vitro and in vivo. Knockdown of LKB1 reversed the effect elicited by shNEU1 in vitro. In conclusion, NEU1 inhibition activates AMPKα via LKB1, and subsequently activates sirt3, thereby regulating fibrosis, inflammation, apoptosis and oxidative stress in diabetic myocardial tissue.


  • 6-Gingerol protects against cardiac remodeling by inhibiting the p38 mitogen-activated protein kinase pathway

    by Shu-Qing Ma, Zhen Guo, Fang-Yuan Liu, Shahzad-Gul Hasan, Dan Yang, Nan Tang, Peng An, Ming-Yu Wang, Hai-Ming Wu, Zheng Yang, et al.

    6-Gingerol, a pungent ingredient of ginger, has been reported to possess anti-inflammatory and antioxidant activities, but the effect of 6-gingerol on pressure overload-induced cardiac remodeling remains inconclusive. In this study, we investigated the effect of 6-gingerol on cardiac remodeling in in vivo and in vitro models, and to clarify the underlying mechanisms. C57BL/6 mice were subjected to transverse aortic constriction (TAC), and treated with 6-gingerol (20 mg/kg, ig) three times a week (1 week in advance and continued until the end of the experiment). Four weeks after TAC surgery, the mice were subjected to echocardiography, and then sacrificed to harvest the hearts for analysis. For in vitro study, neonatal rat cardiomyocytes and cardiac fibroblasts were used to validate the protective effects of 6-gingerol in response to phenylephrine (PE) and transforming growth factor-β (TGF-β) challenge. We showed that 6-gingerol administration protected against pressure overload-induced cardiac hypertrophy, fibrosis, inflammation, and dysfunction in TAC mice. In the in vitro study, we showed that treatment with 6-gingerol (20 μM) blocked PE-induced-cardiomyocyte hypertrophy and TGF-β-induced cardiac fibroblast activation. Furthermore, 6-gingerol treatment significantly decreased mitogen-activated protein kinase p38 (p38) phosphorylation in response to pressure overload in vivo and extracellular stimuli in vitro, which was upregulated in the absence of 6-gingerol treatment. Moreover, transfection with mitogen-activated protein kinase kinase 6 expressing adenoviruses (Ad-MKK6), which specifically activated p38, abolished the protective effects of 6-gingerol in both in vitro and in vivo models. In conclusion, 6-gingerol improves cardiac function and alleviates cardiac remodeling induced by pressure overload in a p38-dependent manner. The present study demonstrates that 6-gingerol is a promising agent for the intervention of pathological cardiac remodeling.